EDX Medical partners with Oxford University to enhance cancer drug safety testing

The Guardant Reveal liquid biopsy test has demonstrated effectiveness in predicting disease recurrence in patients with stage II and higher colorectal cancer (CRC). This was shown through findings from the prospective COSMOS study, which were published

Cancer risk is shaped by a complex interplay of genetics, environment, medical history, and lifestyle. Within the realm of cancer genetics, inherited risk factors are a critical area of study. Understanding the influence of genetic variants,

Cambridge-based life science company, EDX Medical Group plc, has entered into a significant partnership with Caris Life Sciences, a US leader in next-generation AI TechBio and precision medicine. This agreement marks a major milestone for EDX

EDX Medical has entered into a distribution agreement with Caris Life Sciences, a US company specialising in AI-driven precision medicine. This collaboration will see both companies working together to distribute Caris’ advanced molecular profiling services across

EDX Medical Group, a UK-based medical diagnostics company, has entered into a distribution agreement with Caris Life Sciences, a US-based AI and precision medicine firm. This partnership will see the two companies work together to distribute

Andrew Lloyd Webber, renowned for his iconic musicals, has invested in EDX Medical, a pioneering company focused on transforming the diagnosis and treatment of cancer, heart disease, and hospital infections. Founded by scientist Sir Chris Evans

Cancer is fundamentally a genetic disease caused by alterations in the genes that regulate cell growth and reproduction. These alterations, or mutations, can occur due to several factors, such as random errors during cell division, exposure

On 17th October 2024, the Mercure Cardiff Holland House Hotel in Cardiff will host a prestigious black-tie event recognising the key contributors to the STEM (Science, Technology, Engineering, and Maths) sectors in Wales. This event will

Your genome, an extensive set of genetic material composed of approximately 3 billion pieces of DNA, serves as the master instruction manual for your body. Every cell within your body contains this entire genome. If you

Genetic testing involves medical tests to identify specific mutations in a person’s genes. These tests, which are continually evolving, have diverse applications, including assessing cancer risk. Predictive genetic testing, in particular, looks for inherited gene mutations

Guardant Health Japan Corp announced its submission of a regulatory application to Japan’s Ministry of Health, Labour and Welfare (MHLW) for the approval of the Guardant360® CDx comprehensive genomic profiling panel. This submission aims to use

In cancer treatment, understanding the tumour is crucial for guiding therapy. The current standard for tumour analysis is the invasive needle or surgical biopsy. However, these biopsies have limitations, including invasiveness, cost, and sometimes inaccessibility of

EDX Medical is introducing a state-of-the-art testing service in the UK to identify the risk of hereditary cancer. This comprehensive hereditary germline cancer test is meticulously designed to predict if family members of cancer patients are

EDX Medical, based in Cambridge, UK, is launching a new diagnostic tool in the UK designed to identify patients’ risk of developing hereditary cancer. This diagnostic tool performs germline testing, which can determine whether mutations in